InnovAge stock surged 14.6% in pre-market activity after the company released fiscal fourth-quarter and full-year 2026 results following the previous session's close. The report signaled a marked financial recovery that outpaced market expectations and drove the company-specific rally.
For the full fiscal year, InnovAge recorded adjusted EBITDA of $94.6 million, an increase of approximately 175% year-over-year. Revenue for the period rose 15.9% to $989.7 million. Company management attributed revenue growth to higher participant enrollment and stronger capitation rates.
The company narrowed its net loss to $0.7 million for fiscal 2026, compared with a $35.3 million loss in fiscal 2025. Management said that one-time legal accruals were the principal factor preventing an outright profitable year, indicating that without those items the company would have reported a profitable result.
Looking ahead, InnovAge issued fiscal 2027 guidance calling for revenue in the range of $1.05 billion to $1.085 billion and adjusted EBITDA of $105 million to $115 million. The guidance signals continued margin expansion as the company works toward its long-term target of above 10%.
On a quarterly basis, InnovAge reported earnings per share of $0.06, a slight shortfall versus analyst estimates. However, quarterly revenue materially exceeded the consensus forecast of $238.22 million, reinforcing the top-line strength seen for the year.
Chief executive officer Patrick Blair characterized fiscal 2026 as "an exceptional year for InnovAge and a key milestone in the transformation of the company." He outlined a new strategic phase focused on scaling the business through technology, integrating artificial intelligence, and pursuing potential acquisitions as levers for future growth.
The market backdrop offered little support for the move, with the S&P 500, Dow Jones, and Nasdaq all trading modestly lower on the day. That divergence underscores that the sharp move in InnovAge shares was driven by company-specific fundamentals rather than broader sector or macro momentum.
Within the PACE-focused senior care segment, where InnovAge competes alongside firms such as P3 Health Partners, there were no comparable company-level catalysts reported that day. That contrast further highlights the idiosyncratic nature of InnovAge's advance.
Analysts and traders pointed to the combination of a dramatic year-over-year EBITDA improvement, a near-breakeven net income outcome, a revenue beat, and forward guidance as the factors that together propelled INNV sharply higher in pre-market trading. The move pushed the stock toward its 52-week high of $12.64.
Market implications
The results and guidance provide a clear signal that InnovAge is pursuing margin recovery and top-line growth, with management emphasizing technology and strategic scale. Investors reacted quickly to the improved profitability metrics and the company's forward-looking targets.